U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402369) titled 'Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia' on Feb. 03.
Brief Summary: Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia. The primary outcome is the percentage of participants who achieve menstrual blood loss =50% from baseline.
Study Design This is a placebo-controlled trial. Participants will be randomized to receive either CMS-D002 capsules or a matching placebo for 12 weeks.
Participant Responsibilities Take one CMS-D002 capsule or placebo daily for 12 weeks. Complete an electronic patien...